Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea
· Delayed Price · Currency is KRW 49,500
-2,000 (-3.88%)
Apr 29, 2026, 3:30 PM KST
Hanall Biopharma Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 2,513,652 | 2,221,619 | 1,959,952 | 2,245,705 | 902,290 | 1,077,892 | Upgrade
|
| Market Cap Growth | 85.45% | 13.35% | -12.72% | 148.89% | -16.29% | -43.84% | Upgrade
|
| Enterprise Value | 2,520,826 | 2,211,037 | 1,934,197 | 2,185,410 | 836,710 | 991,822 | Upgrade
|
| Last Close Price | 49500.00 | 43750.00 | 38650.00 | 44300.00 | 17800.00 | 21050.00 | Upgrade
|
| PE Ratio | - | - | - | 640.06 | 3588.03 | 121.16 | Upgrade
|
| Forward PE | 1322.97 | - | 117.15 | 261.09 | 112.30 | 55.04 | Upgrade
|
| PS Ratio | 16.20 | 14.32 | 14.11 | 16.65 | 8.20 | 10.61 | Upgrade
|
| PB Ratio | 15.55 | 13.74 | 11.64 | 12.06 | 5.36 | 6.59 | Upgrade
|
| P/TBV Ratio | 15.99 | 14.13 | 11.96 | 12.18 | 5.43 | 6.68 | Upgrade
|
| P/FCF Ratio | - | - | 253.93 | 82.47 | 40.22 | - | Upgrade
|
| P/OCF Ratio | - | - | 209.40 | 75.76 | 35.71 | 1283.40 | Upgrade
|
| PEG Ratio | - | 19.09 | 19.09 | 19.09 | 19.09 | 19.09 | Upgrade
|
| EV/Sales Ratio | 16.24 | 14.25 | 13.92 | 16.20 | 7.61 | 9.76 | Upgrade
|
| EV/EBITDA Ratio | - | 1134.12 | 577.20 | 437.93 | 183.55 | 77.34 | Upgrade
|
| EV/EBIT Ratio | - | - | 8392.22 | 1253.51 | 555.66 | 98.21 | Upgrade
|
| EV/FCF Ratio | -766.59 | - | 250.60 | 80.26 | 37.30 | - | Upgrade
|
| Debt / Equity Ratio | 0.20 | 0.20 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Debt / EBITDA Ratio | 16.37 | 16.37 | 0.43 | 0.26 | 0.29 | 0.10 | Upgrade
|
| Debt / FCF Ratio | - | - | 0.19 | 0.05 | 0.06 | - | Upgrade
|
| Net Debt / Equity Ratio | 0.04 | 0.04 | -0.14 | -0.30 | -0.31 | -0.48 | Upgrade
|
| Net Debt / EBITDA Ratio | 3.68 | 3.68 | -6.94 | -11.06 | -11.54 | -6.18 | Upgrade
|
| Net Debt / FCF Ratio | -2.18 | -2.18 | -3.01 | -2.03 | -2.35 | 21.04 | Upgrade
|
| Asset Turnover | 0.71 | 0.71 | 0.61 | 0.60 | 0.53 | 0.49 | Upgrade
|
| Inventory Turnover | 1.96 | 1.96 | 1.88 | 2.08 | 2.11 | 2.05 | Upgrade
|
| Quick Ratio | 0.99 | 0.99 | 1.29 | 2.10 | 2.97 | 4.35 | Upgrade
|
| Current Ratio | 1.91 | 1.91 | 2.46 | 3.02 | 3.92 | 5.37 | Upgrade
|
| Return on Equity (ROE) | -3.37% | -3.37% | -1.02% | 1.98% | 0.15% | 5.16% | Upgrade
|
| Return on Assets (ROA) | -0.46% | -0.46% | 0.06% | 0.48% | 0.46% | 3.02% | Upgrade
|
| Return on Invested Capital (ROIC) | -1.02% | -1.03% | 0.17% | 1.41% | 0.20% | 11.52% | Upgrade
|
| Return on Capital Employed (ROCE) | -0.90% | -0.90% | 0.10% | 0.90% | 0.80% | 5.70% | Upgrade
|
| Earnings Yield | -0.22% | -0.25% | -0.09% | 0.16% | 0.03% | 0.83% | Upgrade
|
| FCF Yield | -0.13% | -0.15% | 0.39% | 1.21% | 2.49% | -0.35% | Upgrade
|
| Buyback Yield / Dilution | -0.13% | -0.13% | -0.04% | 0.24% | 0.76% | -0.05% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.